Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma
Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma
复制标题
DOI：
10.1186/s13104-020-05110-5
复制
发表时间：
2020-06-10
影响因子：
1.8
通讯作者：
Ehlers, Margret
中科院分区：
文献类型：
--
作者：
Haase, Matthias;Thiel, Anne;Ehlers, Margret
目的成纤维细胞生长因子受体（FGFR）2对小鼠肾上腺发育的调控作用。此外，FGFR 2介导的信号传导已被证明可以防止肾上腺皮质前体细胞的凋亡并增强其增殖。Wingless/Int-1（WNT）/β连环蛋白通路的激活作为肾上腺皮质肿瘤发生的关键机制，与其他细胞类型中的FGFR 2信号传导有关。因此，我们假设FGFR 2表达也可能在肾上腺皮质癌（ACC）中发挥作用。我们进行了一项初步研究，并分析了FGFR 2的蛋白表达在26 ACC免疫组化技术。CTNNB 1突变状态和临床数据与FGFR 2表达相关。结果我们观察到不同肿瘤样本之间FGFR 2表达的高度变异性。有一个ACC的子集具有相对较高的FGFR 2核表达。我们没有发现CTNNB 1突变状态或临床特征与FGFR 2表达之间存在明确的相关性。我们的结论是，FGFR信号在肾上腺皮质癌中发挥作用。我们的数据鼓励进一步研究ACC中的FGFR信号传导，特别是因为FGFR信号传导的新抑制剂已经进入治疗其他癌症类型的临床试验。
Objective Fibroblast growth factor receptor (FGFR) 2 regulates the development of the adrenal gland in mice. In addition, FGFR2-mediated signalling has been shown to prevent apoptosis and to enhance proliferation in adrenocortical precursor cells. The activation of the Wingless/Int-1 (WNT)/beta catenin pathway as a key mechanism of adrenocortical tumourigenesis has been linked to FGFR2 signalling in other cell types. Therefore we hypothesised that FGFR2 expression may also play a role in adrenocortical carcinoma (ACC). We conducted a pilot study and analysed protein expression of FGFR2 in 26 ACCs using immunohistochemistry technique. Data on theCTNNB1mutation status and clinical data were correlated to the expression of FGFR2. Results We observed a high variability in FGFR2 expression between the different tumour samples. There was a subset of ACC with comparatively high nuclear expression of FGFR2. We did not find a clear association between theCTNNB1mutational status or clinical features and the FGFR2 expression. We conclude that FGFR signalling plays a role in adrenocortical carcinoma. Our data encourages further investigations of FGFR signalling in ACC, especially since new inhibitors of FGFR signalling are already entering clinical trials for the treatment of other cancer types.